Eris Lifesciences Limited (ERIS.NS)
INR 1493.5
(4.29%)
INR 1493.5
(4.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.18 Billion INR | 16.73% |
| 2022 | 4.21 Billion INR | -0.67% |
| 2021 | 4.24 Billion INR | 9.52% |
| 2020 | 3.87 Billion INR | 20.43% |
| 2019 | 3.21 Billion INR | 4.2% |
| 2018 | 3.08 Billion INR | 4.18% |
| 2017 | 2.96 Billion INR | 20.74% |
| 2016 | 2.45 Billion INR | 59.3% |
| 2015 | 1.54 Billion INR | 45.46% |
| 2014 | 1.05 Billion INR | 12.41% |
| 2013 | 942.73 Million INR | 8.84% |
| 2012 | 866.15 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.74 Billion INR | 84.12% |
| 2024 Q2 | 1.84 Billion INR | 5.73% |
| 2023 Q4 | 945.31 Million INR | -29.45% |
| 2023 Q1 | 1.28 Billion INR | 52.0% |
| 2023 Q3 | 1.33 Billion INR | -5.99% |
| 2023 FY | 4.92 Billion INR | 16.73% |
| 2023 Q2 | 1.42 Billion INR | 10.62% |
| 2022 Q3 | 1.09 Billion INR | -14.42% |
| 2022 Q4 | 847.68 Million INR | -22.62% |
| 2022 Q1 | 1.05 Billion INR | 27.75% |
| 2022 FY | 4.21 Billion INR | -0.67% |
| 2022 Q2 | 1.28 Billion INR | 21.03% |
| 2021 Q2 | 1.24 Billion INR | 11.47% |
| 2021 Q4 | 827.88 Million INR | -21.04% |
| 2021 FY | 4.24 Billion INR | 9.52% |
| 2021 Q1 | 1.12 Billion INR | 32.96% |
| 2021 Q3 | 1.04 Billion INR | -16.03% |
| 2020 Q3 | 966.25 Million INR | -15.39% |
| 2020 Q2 | 1.14 Billion INR | 21.97% |
| 2020 Q1 | 936.32 Million INR | 37.11% |
| 2020 Q4 | 842.41 Million INR | -12.82% |
| 2020 FY | 3.87 Billion INR | 20.43% |
| 2019 Q2 | 981.14 Million INR | 5.5% |
| 2019 FY | 3.21 Billion INR | 4.2% |
| 2019 Q3 | 640.83 Million INR | -34.69% |
| 2019 Q4 | 682.9 Million INR | 6.56% |
| 2019 Q1 | 930.03 Million INR | 74.37% |
| 2018 Q1 | 812.76 Million INR | 29.7% |
| 2018 Q4 | 533.37 Million INR | -36.45% |
| 2018 FY | 3.08 Billion INR | 4.18% |
| 2018 Q2 | 924.07 Million INR | 13.7% |
| 2018 Q3 | 839.32 Million INR | -9.17% |
| 2017 FY | 2.96 Billion INR | 20.74% |
| 2017 Q4 | 626.64 Million INR | -15.78% |
| 2017 Q1 | 668.13 Million INR | 59.86% |
| 2017 Q2 | 924.89 Million INR | 38.43% |
| 2017 Q3 | 744.05 Million INR | -19.55% |
| 2016 Q1 | 681.82 Million INR | 0.0% |
| 2016 Q3 | 663.92 Million INR | -4.04% |
| 2016 FY | 2.45 Billion INR | 59.3% |
| 2016 Q4 | 417.96 Million INR | -37.05% |
| 2016 Q2 | 691.85 Million INR | 1.47% |
| 2015 FY | 1.54 Billion INR | 45.46% |
| 2014 FY | 1.05 Billion INR | 12.41% |
| 2013 FY | 942.73 Million INR | 8.84% |
| 2012 FY | 866.15 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sigachi Industries Limited | 1.47 Billion INR | -251.566% |
| Ind-Swift Limited | 1.22 Billion INR | -322.665% |
| Innova Captab Limited | 2.53 Billion INR | -104.535% |
| Aarti Drugs Limited | 7.14 Billion INR | 27.515% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -65.65% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Sakar Healthcare Limited | 495.5 Million INR | -945.743% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 95.042% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 234.489% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | -15.821% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -18771.44% |
| Morepen Laboratories Limited | 4.17 Billion INR | -24.148% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Wanbury Limited | 1.7 Billion INR | -203.52% |
| Laurus Labs Limited | 3.94 Billion INR | -31.229% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -33.186% |
| Gufic Biosciences Limited | 2.89 Billion INR | -79.063% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 42.292% |
| Alembic Limited | 767.77 Million INR | -574.905% |
| Hikal Limited | 1.49 Billion INR | -246.789% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 10.01% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 20.31% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | -4.846% |
| Themis Medicare Limited | 1.3 Billion INR | -297.644% |
| RPG Life Sciences Limited | 2.29 Billion INR | -126.049% |
| Lupin Limited | 27.75 Billion INR | 81.333% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -734.379% |
| Wockhardt Limited | 140 Million INR | -3601.229% |
| Vaishali Pharma Limited | 6.29 Million INR | -82227.931% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -2320.912% |
| NATCO Pharma Limited | 25.96 Billion INR | 80.041% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 0.14% |
| FDC Limited | 3.03 Billion INR | -70.803% |
| Divi's Laboratories Limited | 18.31 Billion INR | 71.7% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2390.613% |
| Windlas Biotech Limited | 1.29 Billion INR | -298.934% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.032% |
| Mankind Pharma Limited | 40.86 Billion INR | 87.321% |
| Venus Remedies Limited | 534.65 Million INR | -869.178% |
| ZIM Laboratories Limited | 1.09 Billion INR | -371.875% |
| Neuland Laboratories Limited | 5.31 Billion INR | 2.564% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 31.292% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -171.817% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 88.585% |
| Bal Pharma Limited | 214.56 Million INR | -2314.943% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 92.349% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -839.417% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 28.284% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -320.935% |
| Shilpa Medicare Limited | 3.76 Billion INR | -37.754% |
| Orchid Pharma Limited | 2.36 Billion INR | -119.464% |
| Albert David Limited | 1.33 Billion INR | -288.302% |
| Ajanta Pharma Limited | 19.67 Billion INR | 73.667% |
| Hester Biosciences Limited | 364.77 Million INR | -1320.544% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -12.459% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -85.991% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -182946.22% |
| Granules India Limited | 6.52 Billion INR | 20.626% |
| Alkem Laboratories Limited | 19.46 Billion INR | 73.375% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -2080.299% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -24985.786% |
| Medico Remedies Limited | 277.11 Million INR | -1769.86% |
| Ipca Laboratories Limited | 29.59 Billion INR | 82.492% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1978.916% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -157.921% |
| Brooks Laboratories Limited | -72.25 Million INR | 7271.732% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 79.547% |
| Suven Life Sciences Limited | -1.22 Billion INR | 522.714% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 0.844% |
| Indoco Remedies Limited | 1.52 Billion INR | -239.919% |
| Alpa Laboratories Limited | 61.51 Million INR | -8323.506% |
| Lasa Supergenerics Limited | -458 Million INR | 1231.368% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 225.921% |